Shamburg News · 8-K filed Oct 19, 2026, 8:00 AM EDT
CorMedix Announces FDA Acceptance of REZZAYO sNDA for Prophylaxis with Priority Review
CRMD · CorMedix Inc.
- Other event
- Other
- Materiality: medium
On October 19, 2026, CorMedix announced that the FDA accepted for filing the supplemental New Drug Application for REZZAYO (rezafungin) for prophylaxis of invasive fungal disease, submitted by partner Mundipharma. The FDA granted Priority Review with a PDUFA target action date in Q1 2027. The press release was furnished as Exhibit 99.1 under Item 7.01.
Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001213900-26-110477.
Written from the filing by Shamburg Markets. Figures are as reported by the company.